Yakult Honsha in 50 million-euro deal to market AEterna Zentaris' perifosine in Japan

Canada’s AEterna Zentaris (Nasdaq: AEZS) has entered into a deal with Japan’s Yakult Honsha (TOY: 2267) for the development, registration and marketing of perifosine, AEterna Zentaris' lead anti-cancer compound, in Japan. Perifosine, a novel oral PI3K/Akt inhibitor, is currently in two Phase III programs for the treatment of colorectal cancer and multiple myeloma in the USA and Europe.

Under the terms of the deal, AEterna Zentaris will receive an initial 6 million euros ($8.3 million) upfront payment and will be entitled to receive additional up to 44 million euros ($60.9 million) payments upon achieving certain pre-established milestones including clinical and regulatory events in Japan. Furthermore, AEterna Zentaris will be supplying perifosine to Yakult Honsha on a cost-plus-basis and be entitled to receive double-digit royalties on future net sales of perifosine in Japan. Yakult Honsha will be responsible for the development, registration and commercialization in Japan.

"We are delighted to have a partner such as Yakult Honsha who has a proven track record in oncology and particularly in colon cancer, one of the main indications being targeted with perifosine. This partnership marks another important milestone in our quest to bring perifosine to market worldwide which could provide cancer patients with a novel treatment option. Furthermore, perifosine could generate significant long-term revenue for AEterna Zentaris while building value for our shareholders," said Juergen Engel, president and chief executive of the Canadian firm.